Canopy Growth Corporation

NasdaqGS:CGC 株式レポート

時価総額：US$410.7m

Canopy Growth 過去の業績

過去 基準チェック /06

Canopy Growthは26.3%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は減少しており、年平均17.9%の割合である。

主要情報

26.29%

収益成長率

40.39%

EPS成長率

Pharmaceuticals 業界の成長5.95%
収益成長率-17.94%
株主資本利益率-43.17%
ネット・マージン-117.57%
次回の業績アップデート15 Jun 2026

最近の業績更新

Recent updates

Seeking Alpha • Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

Canopy Growth: Zombie Financials As Delisting Threat Looms

Summary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
Seeking Alpha • Mar 30

Cannabis Investors Should Sell Canopy Growth

Summary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak

Summary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results

Summary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Crashing Canopy Growth Is Still Not A Buy

Summary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty

Summary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Avoid Canopy Growth

Summary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Seeking Alpha • Oct 05

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Summary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Summary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Canopy Growth: Another Ugly Cannabis Report

Summary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
Seeking Alpha • Apr 26

Canopy Growth Set For U.S. Cannabis Markets

Summary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Canopy Growth Is Climbing, But It Won't Last

Summary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Summary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Summary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Avoid Canopy Growth After Failed Equity Sale

Summary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha

収支内訳

Canopy Growth の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:CGC 収益、費用、利益 ( )CAD Millions
日付収益収益G+A経費研究開発費
31 Dec 25278-3271220
30 Sep 25279-3871310
30 Jun 25275-5161370
31 Mar 25269-6041460
31 Dec 24277-4771790
30 Sep 24280-5861890
30 Jun 24287-6021960
31 Mar 24297-4842090
31 Dec 23293-9992320
30 Sep 23299-9912670
30 Jun 23317-1,0253080
31 Mar 23333-3,0793350
31 Dec 22367-3,0514010
30 Sep 22423-2,9384450
30 Jun 22466-2,7665170
31 Mar 22476-2554940
31 Dec 21557-4285880
30 Sep 21569-1,2236160
30 Jun 21572-1,2446190
31 Mar 21547-1,7456640
31 Dec 20506-2,3487650
30 Sep 20477-1,5358430
30 Jun 20419-1,2449380
31 Mar 20399-1,3219930
31 Dec 19385-415961-5
30 Sep 19344-2568810
30 Jun 19291-8327940
31 Mar 19226-7366420
31 Dec 18155-3984704
30 Sep 1894-464350-1
30 Jun 1888-1481990
31 Mar 1878-671490
31 Dec 1770-21950
30 Sep 1758-19661
30 Jun 1749-13501
31 Mar 1740-8391
31 Dec 1630-1292
30 Sep 1624-7251
30 Jun 1618-8211
31 Mar 1613-3171
31 Dec 1580130
30 Sep 1561110
30 Jun 153-5100

質の高い収益: CGCは現在利益が出ていません。

利益率の向上: CGCは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CGCは利益を出していないが、過去 5 年間で年間26.3%の割合で損失を削減してきた。

成長の加速: CGCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CGCは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。

株主資本利益率

高いROE: CGCは現在利益が出ていないため、自己資本利益率 ( -43.17% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/22 19:10
終値2026/05/22 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Canopy Growth Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23

アナリスト機関
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)